<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967862</url>
  </required_header>
  <id_info>
    <org_study_id>13365</org_study_id>
    <secondary_id>NCI-2013-01924</secondary_id>
    <secondary_id>13365</secondary_id>
    <nct_id>NCT01967862</nct_id>
  </id_info>
  <brief_title>Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer</brief_title>
  <official_title>F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well fluorine F 18 sodium fluoride positron emission&#xD;
      tomography (PET)/computed tomography (CT) and whole body and axial magnetic resonance imaging&#xD;
      (MRI) work in finding metastases in patients with recurrent prostate cancer. New imaging&#xD;
      techniques, such as fluorine F 18 sodium fluoride PET/CT and whole body and axial MRI, may be&#xD;
      more effective than standard CT and bone scan in finding metastatic prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the proportion of patients with biochemically-recurrent prostate cancer (PC)&#xD;
      in whom imaging with whole body (WB)/axial MRI and F-18 NaF (fluorine F 18 sodium fluoride)&#xD;
      PET/CT results in detection of metastatic disease not visualized on CT scan and bone scan.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the percent of eligible patients with negative, indeterminate and positive CT&#xD;
      scan/bone scan and targeted X-rays if done.&#xD;
&#xD;
      II. To determine the proportion of patients with biochemically-recurrent PC in whom&#xD;
      recurrence in the prostate bed can be visualized using MRI in the absence of detection using&#xD;
      CT scan.&#xD;
&#xD;
      III. To correlate the presence of metastatic disease detected using WB/axial MRI and/or F-18&#xD;
      NaF PET/CT with the predicted 6-year probability of progression-free survival based on the&#xD;
      Memorial Sloan Kettering Cancer Center salvage radiation therapy (RT) PC nomogram, and with&#xD;
      prostate-specific antigen (PSA) level at baseline.&#xD;
&#xD;
      IV. To compare the role of axial MRI of the spine to WB/axial MRI with respect to their&#xD;
      ability to identify sites of disease. Similarly, to evaluate the relative contribution of&#xD;
      F-18 NaF PET and WB/axial MRI.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients first undergo CT scan and bone scan. Patients with negative results from the CT and&#xD;
      bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using&#xD;
      3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.&#xD;
&#xD;
      After completion of study, patients are followed up at 4-6 months and periodically until week&#xD;
      52.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">September 17, 2018</completion_date>
  <primary_completion_date type="Actual">September 17, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Eligible Patients With Positive CT Scan/Bone Scan, MRI and PET Scan.</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Count of eligible patients with positive CT chest, abdomen, pelvis scan, positive WB/axial MRI, positive F-18 NaF PET/CT and positive Bone scan for detection of metastatic disease.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Recurrent Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>Undergo CT</description>
    <arm_group_label>Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)</arm_group_label>
    <other_name>tomography, computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone scan</intervention_name>
    <description>Undergo bone scan</description>
    <arm_group_label>Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>3-Tesla magnetic resonance imaging</intervention_name>
    <description>Undergo axial MRI</description>
    <arm_group_label>Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)</arm_group_label>
    <other_name>3-Tesla MRI</other_name>
    <other_name>3T MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diffusion-weighted magnetic resonance imaging</intervention_name>
    <description>Undergo WB MRI</description>
    <arm_group_label>Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)</arm_group_label>
    <other_name>diffusion-weighted MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fluorine F 18 sodium fluoride</intervention_name>
    <description>Undergo fluorine F 18 sodium fluoride PET/CT</description>
    <arm_group_label>Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)</arm_group_label>
    <other_name>18 F-NaF</other_name>
    <other_name>F-18 NaF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>computed tomography</intervention_name>
    <description>Undergo fluorine F 18 sodium fluoride PET/CT</description>
    <arm_group_label>Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)</arm_group_label>
    <other_name>tomography, computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo fluorine F 18 sodium fluoride PET/CT</description>
    <arm_group_label>Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (CT, bone scan, WB/axial MRI, F18 NaF PET/CT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  History of prior radical prostatectomy for prostate cancer&#xD;
&#xD;
          -  Two PSA values &gt;= 0.2 ng/mL at least 4 weeks after prostatectomy&#xD;
&#xD;
          -  Patients who have started radiographic evaluation and underwent CT scan and/or bone&#xD;
             scan prior to registration to the study will be able to participate under a late&#xD;
             registration provision, provided that the more modern scans (WB/axial MRI and F-18 NaF&#xD;
             PET/CT) can be completed within 8 weeks after CT scan and bone scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with known metastatic disease&#xD;
&#xD;
          -  PSA recurrence not verified by elevated PSA as discussed in the eligibility section&#xD;
&#xD;
          -  Patients who initiated androgen deprivation therapy or other systemic therapy&#xD;
             (chemotherapy, immunotherapy, targeted therapy) for PSA recurrence; nutritional&#xD;
             supplements used for treatment of PSA recurrence will be allowed&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cy Stein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope South Pasadena</name>
      <address>
        <city>South Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <results_first_submitted>August 26, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2020</results_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Listerine</mesh_term>
    <mesh_term>Fluorides</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT01967862/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (CT, Bone Scan, WB/Axial MRI, F18 NaF PET/CT)</title>
          <description>Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.&#xD;
computed tomography: Undergo CT&#xD;
bone scan: Undergo bone scan&#xD;
3-Tesla magnetic resonance imaging: Undergo axial MRI&#xD;
diffusion-weighted magnetic resonance imaging: Undergo WB MRI&#xD;
fluorine F 18 sodium fluoride: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
computed tomography: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
positron emission tomography: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic (CT, Bone Scan, WB/Axial MRI, F18 NaF PET/CT)</title>
          <description>Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.&#xD;
computed tomography: Undergo CT&#xD;
bone scan: Undergo bone scan&#xD;
3-Tesla magnetic resonance imaging: Undergo axial MRI&#xD;
diffusion-weighted magnetic resonance imaging: Undergo WB MRI&#xD;
fluorine F 18 sodium fluoride: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
computed tomography: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
positron emission tomography: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="49" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Eligible Patients With Positive CT Scan/Bone Scan, MRI and PET Scan.</title>
        <description>Count of eligible patients with positive CT chest, abdomen, pelvis scan, positive WB/axial MRI, positive F-18 NaF PET/CT and positive Bone scan for detection of metastatic disease.</description>
        <time_frame>Up to 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (CT, Bone Scan, WB/Axial MRI, F18 NaF PET/CT)</title>
            <description>Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.&#xD;
computed tomography: Undergo CT&#xD;
bone scan: Undergo bone scan&#xD;
3-Tesla magnetic resonance imaging: Undergo axial MRI&#xD;
diffusion-weighted magnetic resonance imaging: Undergo WB MRI&#xD;
fluorine F 18 sodium fluoride: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
computed tomography: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
positron emission tomography: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
laboratory biomarker analysis: Correlative studies</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Eligible Patients With Positive CT Scan/Bone Scan, MRI and PET Scan.</title>
          <description>Count of eligible patients with positive CT chest, abdomen, pelvis scan, positive WB/axial MRI, positive F-18 NaF PET/CT and positive Bone scan for detection of metastatic disease.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive CT Scan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Bone Scan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive MRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive PET</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event occurred over a period of 1 year and 10 months.</time_frame>
      <desc>&quot;Other Adverse Events&quot; include all events that were not severe adverse events regardless of grade or relation to treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (CT, Bone Scan, WB/Axial MRI, F18 NaF PET/CT)</title>
          <description>Patients first undergo CT scan and bone scan. Patients with negative results from the CT and bone scans then undergo WB MRI scan using diffusion-weighted MRI, axial MRI scan using 3-Tesla MRI, and fluorine F 18 sodium fluoride PET/CT scan.&#xD;
computed tomography: Undergo CT&#xD;
bone scan: Undergo bone scan&#xD;
3-Tesla magnetic resonance imaging: Undergo axial MRI&#xD;
diffusion-weighted magnetic resonance imaging: Undergo WB MRI&#xD;
fluorine F 18 sodium fluoride: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
computed tomography: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
positron emission tomography: Undergo fluorine F 18 sodium fluoride PET/CT&#xD;
laboratory biomarker analysis: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul Frankel, Ph.D.</name_or_title>
      <organization>City of Hope</organization>
      <phone>626-218-5265</phone>
      <email>pfrankel@coh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

